Antiresorptive Therapy in the Management of Cancer Treatment-Induced Bone Loss

Ashwani Garg, Kim Leitzel, Suhail Ali, Allan Lipton

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Cancer treatment-induced bone loss treatment has an important role to prevent bone loss-related events like fracture, significant morbidity, mortality, disfigurement and loss of self-esteem, and health-care expenditure. Numerous factors, including treatment regimens and bone metastasis, increase the risk of osteoporosis or local bone destruction in most breast and prostate cancer patients. Cytotoxic chemotherapies, radiation, and hormonal therapies can lead to premature menopause and decrease bone mineral density. Over 60 % of breast cancer patients within 1 year of beginning postoperative adjuvant chemotherapy experience ovarian failure. Also, ovarian ablation and aromatase inhibitors used to treat breast cancer and orchiectomy and androgen deprivation therapy (ADT; to treat prostate cancer) cause substantial bone loss. In this article, we will focus mainly on antiresorptive therapy in the management of cancer treatment-induced bone loss (CTIBL). An understanding of CTIBL is critical for determining how to assess the risk and identify which patients may benefit from preventive therapy.

Original languageEnglish (US)
Pages (from-to)73-77
Number of pages5
JournalCurrent Osteoporosis Reports
Volume13
Issue number2
DOIs
StatePublished - Jan 1 2015

Fingerprint

Bone and Bones
Neoplasms
Therapeutics
Breast Neoplasms
Prostatic Neoplasms
Premature Menopause
Aromatase Inhibitors
Orchiectomy
Adjuvant Chemotherapy
Health Expenditures
Self Concept
Bone Density
Androgens
Osteoporosis
Radiotherapy
Neoplasm Metastasis
Morbidity
Delivery of Health Care
Drug Therapy
Mortality

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism

Cite this

@article{57a0f76990f64a71af01d68394133001,
title = "Antiresorptive Therapy in the Management of Cancer Treatment-Induced Bone Loss",
abstract = "Cancer treatment-induced bone loss treatment has an important role to prevent bone loss-related events like fracture, significant morbidity, mortality, disfigurement and loss of self-esteem, and health-care expenditure. Numerous factors, including treatment regimens and bone metastasis, increase the risk of osteoporosis or local bone destruction in most breast and prostate cancer patients. Cytotoxic chemotherapies, radiation, and hormonal therapies can lead to premature menopause and decrease bone mineral density. Over 60 {\%} of breast cancer patients within 1 year of beginning postoperative adjuvant chemotherapy experience ovarian failure. Also, ovarian ablation and aromatase inhibitors used to treat breast cancer and orchiectomy and androgen deprivation therapy (ADT; to treat prostate cancer) cause substantial bone loss. In this article, we will focus mainly on antiresorptive therapy in the management of cancer treatment-induced bone loss (CTIBL). An understanding of CTIBL is critical for determining how to assess the risk and identify which patients may benefit from preventive therapy.",
author = "Ashwani Garg and Kim Leitzel and Suhail Ali and Allan Lipton",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s11914-014-0252-x",
language = "English (US)",
volume = "13",
pages = "73--77",
journal = "Current Osteoporosis Reports",
issn = "1544-1873",
publisher = "Current Science, Inc.",
number = "2",

}

Antiresorptive Therapy in the Management of Cancer Treatment-Induced Bone Loss. / Garg, Ashwani; Leitzel, Kim; Ali, Suhail; Lipton, Allan.

In: Current Osteoporosis Reports, Vol. 13, No. 2, 01.01.2015, p. 73-77.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Antiresorptive Therapy in the Management of Cancer Treatment-Induced Bone Loss

AU - Garg, Ashwani

AU - Leitzel, Kim

AU - Ali, Suhail

AU - Lipton, Allan

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Cancer treatment-induced bone loss treatment has an important role to prevent bone loss-related events like fracture, significant morbidity, mortality, disfigurement and loss of self-esteem, and health-care expenditure. Numerous factors, including treatment regimens and bone metastasis, increase the risk of osteoporosis or local bone destruction in most breast and prostate cancer patients. Cytotoxic chemotherapies, radiation, and hormonal therapies can lead to premature menopause and decrease bone mineral density. Over 60 % of breast cancer patients within 1 year of beginning postoperative adjuvant chemotherapy experience ovarian failure. Also, ovarian ablation and aromatase inhibitors used to treat breast cancer and orchiectomy and androgen deprivation therapy (ADT; to treat prostate cancer) cause substantial bone loss. In this article, we will focus mainly on antiresorptive therapy in the management of cancer treatment-induced bone loss (CTIBL). An understanding of CTIBL is critical for determining how to assess the risk and identify which patients may benefit from preventive therapy.

AB - Cancer treatment-induced bone loss treatment has an important role to prevent bone loss-related events like fracture, significant morbidity, mortality, disfigurement and loss of self-esteem, and health-care expenditure. Numerous factors, including treatment regimens and bone metastasis, increase the risk of osteoporosis or local bone destruction in most breast and prostate cancer patients. Cytotoxic chemotherapies, radiation, and hormonal therapies can lead to premature menopause and decrease bone mineral density. Over 60 % of breast cancer patients within 1 year of beginning postoperative adjuvant chemotherapy experience ovarian failure. Also, ovarian ablation and aromatase inhibitors used to treat breast cancer and orchiectomy and androgen deprivation therapy (ADT; to treat prostate cancer) cause substantial bone loss. In this article, we will focus mainly on antiresorptive therapy in the management of cancer treatment-induced bone loss (CTIBL). An understanding of CTIBL is critical for determining how to assess the risk and identify which patients may benefit from preventive therapy.

UR - http://www.scopus.com/inward/record.url?scp=84924404218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924404218&partnerID=8YFLogxK

U2 - 10.1007/s11914-014-0252-x

DO - 10.1007/s11914-014-0252-x

M3 - Review article

C2 - 25575469

AN - SCOPUS:84924404218

VL - 13

SP - 73

EP - 77

JO - Current Osteoporosis Reports

JF - Current Osteoporosis Reports

SN - 1544-1873

IS - 2

ER -